TP53 and acute myeloid leukemia: We next investigated a potential association between sensitivity of the AML samples to the drugs and their genetic profiles and found that the most resistant sample AML‐372 had a complex karyotype with biallelic inactivation of TP53 (loss of Chr17 and a somatic mutation in the remaining allele; see Table S3 for genetic information).